Results 121 to 130 of about 253,625 (250)

Current approaches to incorporation of radium-223 in clinical practice

, 2018
BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting ...
Nilsson, S,, Sten Nilsson, Heidenreich, A, Shore, N, Nilsson, S, Axel Heidenreich, Chris Parker, Parker, C, Neal Shore   +8 more
core   +1 more source

Periodontal Medicine Rewired: Mechanisms Linking Periodontitis to Systemic Diseases

Journal of Periodontal Research, EarlyView.
This review reorganizes decades of research in periodontal medicine into a multi‐dimensional framework, illustrating how periodontitis influences systemic health through at least seven interconnected mechanisms. ABSTRACT Periodontitis is now recognized not merely as a localized oral condition but as a systemic disease linked to over 70 communicable and
Mario Romandini, George Hajishengallis, Mike Curtis, Giacomo Baima   +3 more
wiley   +1 more source

Biomarkers of bone metabolism in [223Ra] RaCl2 therapy - association with extent of disease and prediction of overall survival

EJNMMI Research
Background The alpha-emitting radionuclide therapy [223Ra]RaCl2 (Radium-223) improves overall survival (OS) and time to symptomatic skeletal event (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Marie Øbro Fosbøl, Niklas Rye Jørgensen, Peter Meidahl Petersen, Andreas Kjaer, Jann Mortensen   +4 more
doaj   +1 more source

Internal Radiumtherapy Subacute and Chronic Infectious Arthritis

, 1915
Handbill published by the Radium Chemical Company, describing Radium Solutions' therapeutic qualities when treating Rheumatoid ...
Radium Chemical Company
core  

Osteoporosis and Periodontitis: Two‐Way Epidemiological and Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
This review investigates the main mechanistic pathways connecting local periodontitis to systemic osteoporosis. Seven interconnected mechanisms are identified. ABSTRACT Osteoporosis and periodontitis are highly prevalent, chronic inflammatory diseases that constitute a major global health burden.
Jia Chang, Geeta Madhuri Bhuvanagiri, Megan Dulkanchainun, Cunyu Wang   +3 more
wiley   +1 more source

Internal Radiumtherapy Arthritis Deformans

, 1915
Handbill published by the Radium Chemical Company, describing Radium Solutions' therapeutic qualities when treating Arthritis Deformas, now known as Osteoarthritis.Prices (in USD) per Microgram are also ...
Radium Chemical Company
core  

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer - Fig 2

, 2019
A. Kaplan-Meier plot of progression free survival of patients treated with radium-223. B. Kaplan-Meier plot of overall survival of patients treated with radium-223. C.
Colin Rothwell (6743741), Jiaren Zhang (433244), Gabor Kemeny (6743729), Charles Spritzer (6743735), Jason A. Somarelli (6743747), Drew Gerber (6743756), Wen-Chi Foo (6245351), Simon G. Gregory (268051), Santosh Gupta (229634), Thomas Ribar (6743753), Andrew J. Armstrong (6743726), Paraskevi Giannakakou (167989), Catrin Davies (6743738), Susan Halabi (456960), Monika Anand (59584), Patrick Healy (549824), Kathryn Ware (6743744), Beth Leith (6743732), Kris Wood (6743750), Michael R. Zalutsky (2944272), Daniel J. George (3900313)   +20 more
core   +1 more source

Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment

Annals of Nuclear Medicine
Radium-223 is a first alpha-emitting radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases. Although the spread-based bone scan index (BSI) and novel index of the intensity-based two-dimensional ...
Shohei Fukai, H. Daisaki, T. Umeda, Naoki Shimada, Takashi Terauchi, Mitsuru Koizumi   +5 more
semanticscholar   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review

Diagnostics, 2019
Prostate cancer (PCa) is one of the most common cancers in men that usually develops slowly. Since diagnostic methods improved in the last decade and are highly precise, more cancers are diagnosed at an early stage.
Bartosz Malinowski, Michał Wiciński, Nikola Musiała, Ilona Osowska, Mateusz Szostak   +4 more
doaj   +1 more source